Summary
BeiGene, Ltd. (ONC) has filed its 2022 Interim Report for the six months ended June 30, 2022, with the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange. This report, prepared under PRC GAAP, includes detailed research and development (R&D) expenses allocated by key products and other projects. Investors should note that these financial statements differ from U.S. GAAP, and a summary of material differences under U.S. GAAP is provided as an exhibit to this 8-K filing. The primary focus of this filing is the disclosure of R&D expenses under PRC standards. While the STAR Interim Report is publicly available in Chinese, the accompanying U.S. GAAP reconciliation is crucial for investors accustomed to U.S. reporting standards. This information provides a more granular view of BeiGene's investment in its product pipeline, which is a key driver of value for biotechnology and pharmaceutical companies.
Key Highlights
- 1BeiGene, Ltd. filed its 2022 Interim Report (six months ended June 30, 2022) with the Shanghai Stock Exchange's STAR Market.
- 2The STAR Interim Report was prepared in accordance with PRC GAAP and its listing rules.
- 3Key R&D expenses are detailed and allocated by product and project under PRC GAAP.
- 4A summary of material differences between PRC GAAP and U.S. GAAP, including R&D expenses under U.S. GAAP, is provided as Exhibit 99.1.
- 5The STAR Interim Report is available in Chinese on the Shanghai Stock Exchange website.
- 6Information furnished in this 8-K is intended to be supplemental and is not considered 'filed' under Section 18 of the Exchange Act.